CCS Research
CCS Publications
  • Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep 2013;3:1339-45.

  • Jacak J, Schnidar H, Muresan L, Regl G, Frischauf A, Aberger F, et al. Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout. Journal of biotechnology 2013;164:525-30.

  • Pelczar P, Zibat A, van Dop WA, Heijmans J, Bleckmann A, Gruber W, et al. Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfralpha but not kit. Gastroenterology 2013;144:134-44 e6.

  • Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ, et al. Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer cell 2013;23:77-92.

  • Schweigert M, Solymosi N, Dubecz A, Stadlhuber RJ, Ofner D, Stein HJ. Current outcome of esophagectomy in the very elderly: experience of a German high-volume center. The American surgeon 2013;79:754-63.

  • Melchardt T, Weiss L, Pleyer L, Steinkirchner S, Auberger J, Hopfinger G, et al. Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome. Oncology letters 2013;6:1756-8.

  • Neu V, Bielow C, Gostomski I, Wintringer R, Braun R, Reinert K, et al. Rapid and comprehensive impurity profiling of synthetic thyroxine by ultrahigh-performance liquid chromatography-high-resolution mass spectrometry. Analytical chemistry 2013;85:3309-17.

  • Neu V, Bielow C, Schneider P, Braun R, Stuppner H, Reinert K, et al. Plan and evaluate UHPLC-HRMS-Experiments - Example Thyroxine. Nachrichten Aus Der Chemie 2013;61:455-8.

  • Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, et al. CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood 2013;122:3317-21.

  • Neu V, Bielow C, Schneider P, Reiner K, Stuppner H, Huber CG. Investigation of Reaction Mechanisms of Drug Degradation in the Solid State: A Kinetic Study Implementing Ultrahigh-Performance Liquid Chromatography and High-Resolution Mass Spectrometry for Thermally Stressed Thyroxine. Analytical Chemistry 2013;85:2385-90.

  • Wolff F, Loipetzberger A, Gruber W, Esterbauer H, Aberger F, Frischauf AM. Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene 2013;32:5574-81.

  • Bezan A, Hohla F, Meissnitzer T, Greil R. Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. BMC cancer 2013;13:618.

  • Wilmes A, Limonciel A, Aschauer L, Moenks K, Bielow C, Leonard MO, et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. Journal of proteomics 2013;79:180-94.

  • Valentiny C, Mitrovic M, Pleyer L, Steurer M, Willenbacher W, Stauder R. Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia. Wiener klinische Wochenschrift 2013;125:50-3.

  • Illig R, Klieser E, Kiesslich T, Neureiter D. GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers? Gastroenterology research and practice 2013;2013:643084.

  • Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Molecular carcinogenesis 2013.

  • Bach D, Fuereder J, Karbiener M, Scheideler M, Ress AL, Neureiter D, et al. Comprehensive analysis of alterations in the miRNome in response to photodynamic treatment. Journal of photochemistry and photobiology B, Biology 2013;120:74-81.

  • Hoy B, Brandstetter H, Wessler S. The stability and activity of recombinant Helicobacter pylori HtrA under stress conditions. Journal of basic microbiology 2013;53:402-9.

  • Zogg T, Sponring M, Schindler S, Koll M, Schneider R, Brandstetter H, et al. Crystal structures of the viral protease Npro imply distinct roles for the catalytic water in catalysis. Structure 2013;21:929-38.

  • Eckhard U, Schonauer E, Brandstetter H. Structural basis for activity regulation and substrate preference of clostridial collagenases G, H, and T. The Journal of biological chemistry 2013;288:20184-94.

  • Dall E, Brandstetter H. Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation. Proceedings of the National Academy of Sciences of the United States of America 2013;110:10940-5.

  • Boehm M, Haenel I, Hoy B, Brondsted L, Smith TG, Hoover T, et al. Extracellular secretion of protease HtrA from Campylobacter jejuni is highly efficient and independent of its protease activity and flagellum. European journal of microbiology & immunology 2013;3:163-73.

  • Skala W, Goettig P, Brandstetter H. Do-it-yourself histidine-tagged bovine enterokinase: a handy member of the protein engineer's toolbox. Journal of biotechnology 2013;168:421-5.

  • Posselt G, Backert S, Wessler S. The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis. Cell communication and signaling : CCS 2013;11:77.

  • Backert S, Boehm M, Wessler S, Tegtmeyer N. Transmigration route of Campylobacter jejuni across polarized intestinal epithelial cells: paracellular, transcellular or both? Cell communication and signaling : CCS 2013;11:72.

  • Jager T, Neureiter D, Nawara C, Dinnewitzer A, Ofner D, Lamade W. Intrathoracic major duodenal papilla with transhiatal herniation of the pancreas and duodenum: A case report and review of the literature. World journal of gastrointestinal surgery 2013;5:202-6.

  • Kiesslich T, Pichler M, Neureiter D. Epigenetic control of epithelial-mesenchymal-transition in human cancer. Molecular and clinical oncology 2013;1:3-11.

  • Montalbano R, Waldegger P, Quint K, Jabari S, Neureiter D, Illig R, et al. Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells. Translational oncology 2013;6:143-57.

  • P DIF, Montalbano R, Quint K, Alinger B, Kemmerling R, Kiesslich T, et al. The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models. Oncology letters 2013;5:127-34.

  • Berlicki L, Kaske M, Gutierrez-Abad R, Bernhardt G, Illa O, Ortuno RM, et al. Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane beta-amino acids shifts selectivity toward the Y(\(\(4) receptor. Journal of medicinal chemistry 2013;56:8422-31.

  • Wagner A, Kiesslich T, Neureiter D, Friesenbichler P, Puespoek A, Denzer UW, et al. Photodynamic therapy for hilar bile duct cancer: clinical evidence for improved tumoricidal tissue penetration by temoporfin. Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology 2013;12:1065-73.

  • Gnant M, Greil R, Hubalek M, Steger G. Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion. Breast Care (Basel) 2013;8:293-9.

  • Chari NS, Romano RA, Koster MI, Jaks V, Roop D, Flores ER, et al. Interaction between the TP63 and SHH pathways is an important determinant of epidermal homeostasis. Cell death and differentiation 2013;20:1080-8.

  • Gotschel F, Berg D, Gruber W, Bender C, Eberl M, Friedel M, et al. Synergism between Hedgehog-GLI and EGFR signaling in Hedgehog-responsive human medulloblastoma cells induces downregulation of canonical Hedgehog-target genes and stabilized expression of GLI1. PloS one 2013;8:e65403.

  • Unger C, Popescu R, Giessrigl B, Laimer D, Heider S, Seelinger M, et al. The dichloromethane extract of the ethnomedicinal plant Neurolaena lobata inhibits NPM/ALK expression which is causal for anaplastic large cell lymphomagenesis. International journal of oncology 2013;42:338-48.

  • Nagarajan P, Ge Z, Sirbu B, Doughty C, Agudelo Garcia PA, Schlederer M, et al. Histone acetyl transferase 1 is essential for mammalian development, genome stability, and the processing of newly synthesized histones H3 and H4. PLoS genetics 2013;9:e1003518.

  • McGuckin CP, Jurga M, Miller AM, Sarnowska A, Wiedner M, Boyle NT, et al. Ischemic brain injury: a consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction. Archives of biochemistry and biophysics 2013;534:88-97.

  • Namberger K, Weiss L, Krause B, Melchardt T, Greil R. A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p. Eur J Haematol 2013;90:349-50.

  • Lass-Florl C, Mutschlechner W, Aigner M, Grif K, Marth C, Girschikofsky M, et al. Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study. J Clin Microbiol 2013;51:863-8.

  • Taylor N, Melchardt T, Grundbichler M, Strasser M, Egle A, Greil R. Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient. Annals of hematology 2013;92:1001-2.

  • Auberger J, Vogt S, Hopfinger G, Clausen J, Greil R. Topical evening primrose oil for reduction of bortezomib-induced skin reactions. Annals of hematology 2013;92:995-6.

  • Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2013;19:500-7.

  • Melchardt T, Weiss L, Greil R, Egle A. Viral infections and their management in patients with chronic lymphocytic leukemia. Leukemia & lymphoma 2013;54:1602-13.

  • Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer cell 2013;24:167-81.

  • Kenner L. [Viennese Clinical Weekly Review]. Wiener klinische Wochenschrift 2013;125:228-9.

  • Gattelli A, Nalvarte I, Boulay A, Roloff TC, Schreiber M, Carragher N, et al. Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO molecular medicine 2013;5:1335-50.

  • Asslaber D, Grossinger EM, Girbl T, Hofbauer SW, Egle A, Weiss L, et al. Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go? British journal of haematology 2013;160:711-4.

  • Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncology 2013;14:29-37.

  • Girbl T, Hinterseer E, Grossinger EM, Asslaber D, Oberascher K, Weiss L, et al. CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility. Cancer research 2013;73:561-70.

  • Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31:247-55.

  • Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24:640-7.

  • Boll B, Gorgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31:1522-9.

  • Pfeiler G, Stoger H, Dubsky P, Mlineritsch B, Singer C, Balic M, et al. Efficacy of tamoxifen +/- aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. British journal of cancer 2013;108:1408-14.

  • Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, et al. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica 2013;98:264-8.

  • Gaidzik VI, Schlenk RF, Paschka P, Stolzle A, Spath D, Kuendgen A, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 2013;121:4769-77.

  • Keil F, Selzer E, Berghold A, Reinisch S, Kapp KS, De Vries A, et al. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer 2013;49:352-9.

  • Sohns M, Viktorova E, Amos CI, Brennan P, Fehringer G, Gaborieau V, et al. Empirical hierarchical bayes approach to gene-environment interactions: development and application to genome-wide association studies of lung cancer in TRICL. Genetic epidemiology 2013;37:551-9.

  • Scherf DB, Sarkisyan N, Jacobsson H, Claus R, Bermejo JL, Peil B, et al. Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4. Oncogene 2013;32:3329-38.

  • Brenner DR, Brennan P, Boffetta P, Amos CI, Spitz MR, Chen C, et al. Hierarchical modeling identifies novel lung cancer susceptibility variants in inflammation pathways among 10,140 cases and 11,012 controls. Human genetics 2013;132:579-89.

  • Demetriou CA, Chen J, Polidoro S, van Veldhoven K, Cuenin C, Campanella G, et al. Methylome analysis and epigenetic changes associated with menarcheal age. PloS one 2013;8:e79391.

  • Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31:1719-25.

  • Freytag S, Manitz J, Schlather M, Kneib T, Amos CI, Risch A, et al. A network-based kernel machine test for the identification of risk pathways in genome-wide association studies. Human heredity 2013;76:64-75.

  • Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, et al. Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 2013;6:32.

  • Egle A, Asslaber D, Villunger A, Pinon-Hofbauer J. Bid-ding for mercy: twisted killer in action. Cell death and differentiation 2013;20:847-9.

  • Melchardt T, Weiss L, Egle A. [Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?]. Dtsch Med Wochenschr 2013;138:2093-5.

  • Schweigert M, Solymosi N, Dubecz A, Stadlhuber RJ, Muschweck H, Ofner D, et al. Endoscopic stent insertion for anastomotic leakage following oesophagectomy. Annals of the Royal College of Surgeons of England 2013;95:43-7.

  • Schweigert M, Solymosi N, Dubecz A, Ofner D, Stein HJ. Length of nonoperative treatment and risk of pleural empyema in the management of pancreatitis-induced pancreaticopleural fistula. The American surgeon 2013;79:614-9.

  • Schweigert M, Renz M, Dubecz A, Solymosi N, Ofner D, Stein HJ. Pancreaticopleural fistula-induced empyema thoracis: principles and results of surgical management. The Thoracic and cardiovascular surgeon 2013;61:619-25.

  • Schweigert M, Dubecz A, Solymosi N, Ofner D, Stein HJ. Times and trends in the treatment of spontaneous perforation of the esophagus: from Herman Boerhaave to the present age. The American surgeon 2013;79:902-8.

  • Schweigert M, Dubecz A, Ofner D, Stein HJ. Tracheal bronchus associated with recurrent pneumonia. The Ulster medical journal 2013;82:94-6.

  • Schweigert M, Dubecz A, Beron M, Ofner D, Stein HJ. Pulmonary infections imitating lung cancer: clinical presentation and therapeutical approach. Irish journal of medical science 2013;182:73-80.

  • Schweigert M, Dubecz A, Beron M, Ofner D, Stein HJ. Surgical therapy for necrotizing pneumonia and lung gangrene. The Thoracic and cardiovascular surgeon 2013;61:636-41.

  • Schweigert M, Beattie R, Solymosi N, Booth K, Dubecz A, Muir A, et al. Endoscopic stent insertion versus primary operative management for spontaneous rupture of the esophagus (Boerhaave syndrome): an international study comparing the outcome. The American surgeon 2013;79:634-40.

  • Primavesi F, Holzinger J, Ofner D, Hutter J. [Splenic Rupture after Colonoscopy: Case Series and Review of the Literature.]. Zentralblatt fur Chirurgie 2013.

  • Nawara C, Augscholl C, Hutter J, Ofner D, Primavesi F. [Oesophageal GIST at the left tracheobronchial angle: resection with right-sided VATS]. Zentralblatt fur Chirurgie 2013;138:499-501.

  • Kogler P, Kafka-Ritsch R, Ofner D, Sieb M, Augustin F, Pratschke J, et al. Is limited surgery justified in the treatment of T1 colorectal cancer? Surgical endoscopy 2013;27:817-25.

  • Koch OO, Spaun G, Antoniou SA, Rabl C, Kohler G, Emmanuel K, et al. Endoscopic grading of the gastroesophageal flap valve is correlated with reflux activity and can predict the size of the esophageal hiatus in patients with gastroesophageal reflux disease. Surgical endoscopy 2013;27:4590-5.

  • Dubecz A, Solymosi N, Schweigert M, Stadlhuber RJ, Peters JH, Ofner D, et al. Time trends and disparities in lymphadenectomy for gastrointestinal cancer in the United States: a population-based analysis of 326,243 patients. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2013;17:611-8; discussion 8-9.

  • Baselga J, Gomez P, Greil R, Braga S, Climent MA, Wardley AM, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31:2586-92.

  • Weiss L, Hufnagl C, Greil R. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;369:93.

  • Kubicka S, Greil R, Andre T, Bennouna J, Sastre J, Van Cutsem E, et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24:2342-9.

  • Crown JP, Dieras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31:2870-8.

  • Gnant M, Pfeiler G, Stoger H, Mlineritsch B, Fitzal F, Balic M, et al. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. British journal of cancer 2013;109:589-96.

  • Taylor N, Grabmeier-Pfistershammer K, Egle A, Greil R, Rieger A, Ledergerber B, et al. Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level. PloS one 2013;8:e74024.

  • Stenner-Liewen F, Grunwald V, Greil R, Porta C. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2013;13:1021-33.

  • Gampenrieder SP, Rinnerthaler G, Greil R. Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J Oncol 2013;2013:732047.

  • Greil R, Hiddemann W. [Successful cancer therapy: chance and challenges]. Dtsch Med Wochenschr 2013;138:2083.

  • Schlick K, Datz L, Hohla F, Greil R, Hopfinger G. [71-year old woman with neutropenic fever during chemotherapy]. Dtsch Med Wochenschr 2013;138:2091-2.

  • Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. British journal of cancer 2013;109:2959-64.

  • Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. The Lancet Oncology 2013;14:125-33.

  • Dinnewitzer A, Jager T, Nawara C, Buchner S, Wolfgang H, Ofner D. Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer. Diseases of the colon and rectum 2013;56:1134-42.

Translational cancer research at CCS

Bench-to-bedside and bedside-to-bench work

The scientific strategy and conceptual organization of CCS allows both the validation of basic research findings in clinical settings (bench to bedside) and the detailed molecular analysis of clinical observations in predictive in vitro and in vivo model systems (bedside to bench). This bidirectional research strategy accelerates the discovery of novel and innovative therapeutic approaches for personalized cancer therapy. 

Funding & Support

Cancer Cluster Salzburg at SCRI

3rd Medical Department

Paracelsus Medical University Clinics Salzburg

Müllner Hauptstrasse 48, 5020 Salzburg, Austria

Email: ccs@sbg.ac.at

Cancer Cluster Salzburg at PLUS

Department of Biosciences

University of Salzburg

Hellbrunner Strasse 34, 5020 Salzburg, Austria

Email: ccs@sbg.ac.at